Clinical Trial: Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy
Brief Summary: A double-blind follow-up trial assessing the long term safety of Levetiracetam as per adverse events reporting, physical and neurological examination and vital signs
Detailed Summary:
Sponsor: UCB Pharma
Current Primary Outcome: Around 2 years of Safety assessment of levetiracetam via Adverse Events reporting, physical and neurological examination and vital signs
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: UCB Pharma
Dates:
Date Received: September 6, 2005
Date Started: July 2003
Date Completion:
Last Updated: November 25, 2013
Last Verified: September 2009